KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Equity Income (2017 - 2020)

Historic Equity Income for Fulgent Genetics (FLGT) over the last 4 years, with Q4 2020 value amounting to $143000.0.

  • Fulgent Genetics' Equity Income rose 18218.39% to $143000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was -$488000.0, marking a year-over-year increase of 3719.43%. This contributed to the annual value of -$488000.0 for FY2020, which is 3719.43% up from last year.
  • Fulgent Genetics' Equity Income amounted to $143000.0 in Q4 2020, which was up 18218.39% from -$189000.0 recorded in Q3 2020.
  • In the past 5 years, Fulgent Genetics' Equity Income registered a high of $143000.0 during Q4 2020, and its lowest value of -$279000.0 during Q1 2019.
  • In the last 4 years, Fulgent Genetics' Equity Income had a median value of -$193000.0 in 2020 and averaged -$181600.0.
  • Per our database at Business Quant, Fulgent Genetics' Equity Income tumbled by 13428.57% in 2018 and then soared by 18218.39% in 2020.
  • Over the past 4 years, Fulgent Genetics' Equity Income (Quarter) stood at -$247000.0 in 2017, then increased by 5.26% to -$234000.0 in 2018, then grew by 25.64% to -$174000.0 in 2019, then skyrocketed by 182.18% to $143000.0 in 2020.
  • Its Equity Income stands at $143000.0 for Q4 2020, versus -$189000.0 for Q3 2020 and -$193000.0 for Q2 2020.